Oncogene expression in gastroenteropancreatic neuroendocrine tumors: Implications for pathogenesis

Cancer

Volumn 80, Issue 4, 1997, Pages 668-675

  Wang, Da Gong ^a,b   Johnston, Colin F ^a   Buchanan, Keith D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

Carcinoid; Islet cell tumor; Oncoprotein; Pathogenesis

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CARCINOGENESIS; DISEASE ASSOCIATION; GASTRINOMA; GLUCAGONOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; MALIGNANT TRANSFORMATION; NEUROENDOCRINE TUMOR; ONCOGENE; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL;

GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RETROSPECTIVE STUDIES;

EID: 0030842534     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970815)80:4<668::AID-CNCR4>3.0.CO;2-J     Document Type: Article

References (38)

1. Buchanan KD, Johnston CF, O'Hare MMT, Ardill JS, Shaw C, Collins JA, et al. Neuroendocrine tumors. Am J Med 1986;81(Suppl 6B):14-22.
2. Nichols AG. Simple adenoma of pancreas arising from an islet of Langerhans. J Med Res 1902;8:385-95.
3. Kloppel G, Heitz PU. Diffuse endocrine cell system: morphology and functional activity of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res 1990; 118:27-36.
4. Watson RGD, Johnston CF, O'Hare MMT. The frequency of gastrointestinal endocrine tumors in a well-defined population: Northern Ireland 1970-1985. Q J Med 1989;267:647-57.
5. Williams ED, Sandler M. The classification of carcinoid tumors. Lancet 1963;1:238-9.
6. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterisation of erb B-3, a third member of the erb B/epidermal growth factor receptor family: evidence of overexpression on a subset of human mammary tumors. Proc Natl Acad Sci U S A 1988;86:9193-7.
7. Vogt P, Tjian R. jun: a transcriptional regulator turned oncogenic. Oncogene 1988;3:3-7.
8. Roncalli M, Springall DR, Varndell IM, Gaitonde VV, Hamid Q, Ibrahim NBN. Oncoprotein immunoreactivity in human endocrine tumours. J Pathol 1991;163:117-27.
9. Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB, Vogelstein B. Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 1986;233:461-4.
10. Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells for a human colon carcinoma. Proc Natl Acad Sci U S A 1983;80:1707-11.
11. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR. The c-erb B-2 proto-oncogene in human pancreatic cancer. J Pathol 1990;161:195-200.
12. Evers BM, Rady PL, Tyring SK, Sanchez RL, Rajaraman S, Townsend CM, et al. Amplification of the HER-2/ neu protooncogene in human endocrine tumours. Surgery 1992; 112:211-8.
13. Rajkumar T, Goden CR, Lemoine NR, Gullick WJ. Expression of the c-erb B-3 protein in gastrointestinal tract tumors determined by monoclonal antibody RTJ1. J Pathol 1993;170: 271-8.
14. Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, et al. The erb B-3 gene in human pancreatic cancel. J Pathol 1992;168:269-73.
15. Tiniakos DG, Scott LE, Corbett IP, Piggott NH, Hornec H. Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4. J Pathol 1994;172: 19-26.
16. Magrisso IJ, Richmond RE, Carter JH, Pross CB, Gilfillen RA, Carter HW. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas. Lab Invest 1993;69:674-81.
17. Yamanishi D, Buckmeier J, Meyskens F. Expression of c-jun, jun B and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas. J Invest Dermatol 1991;97:349-53.
18. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondria membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
19. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of the apoptosis-suppressing protein bcl-2 in neuroblastoma is associated with unfavourable histology and N-myc amplification. Am J Pathol 1993;143:1543-50.
20. Reed JC, Meister L, Tanaka S, Cuddy M, Yun S, Geyer C, Pleasure D. Differential expression of bcl-2 proto-oncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 1991;51:6529-38.
21. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 1996;77:255-64.
22. Sinicrope FA, Ruan SB, Cleary KR, Stephens C, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
23. Höfler H, Ruhri C, Putz B, Wirnsberger G, Hauser H. Oncogene expression in endocrine pancreatic tumors. Virchows Arch B 1988;55:355-61.
24. Johnston CF, O'Neill AB, O'Hare MMT, Buchanan KD. Neuroendocrine cells within colorectal tumours induced by dimethylhydrazine. Cell Tissue Res 1986;246:205-10.
25. Wang DG, Barros D'Sa AAB, Johnston CF, Buchanan KD. Oncogene expression in carotid body tumors. Cancer 1996; 77:2581-7.
26. Iwahashi H, Hanafusa T, Eguchi Y, Nakajima H, Miyagawa J, Itoh N, et al. Cytokine-induced apoptotic cell death in a mouse pancreatic beta-cell line: inhibition by Bcl-2. Diabetologia 1996;39:530-6.
27. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR. Role for c-Myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992;257:212-4.
28. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
29. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992;359:554-6.
30. Wagner AJ, Small MB, Hay N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol 1993; 13:2432-40.
31. Strasser A, Harris AW, Bath ML, Cory AS. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990;348:331-3.
32. Vaux DL, Cory S, Adama JM. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre B cells. Nature 1988;335:440-2.
33. Moertel CG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961;14: 901-12.
34. Godwin JD. Carcinoid utmours: an analysis of 2837 cases. Cancer 1975;36:560-9.
35. Yu CC, Fletcher CD, Newman PL, Goodlan JR, Burton JC, Levison DA. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (Ag-Nor) staining, and histological grading in gastrointestinal stromal tumors. J Pathol 1992;166:147-52.
36. Fontanini G, Pingitore R, Bigini D, Vignati S, Pepe S, Ruggiero A, et al. Growth fraction in non-small-cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labelling and DNA flow cytometry data. Am J Pathol 1992;141:1285-90.
37. Pelosi G, Zamboni G, Goglioni C, Rodella S, Bresaola E, Ia-cono C, et al. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am J Surg Pathol 1992;16: 1215-25.
38. Wang DG, Johnston CF, Anderson N, Sloan JM, Buchanan KD. Over-expression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 1995;175:397-401.